Table 2.
Absolute and relative frequencies of treatment modalities of young mothers and the OVIS participants with breast cancer (BC)
| Young mothers with BC, n (%) |
Women with BC from OVIS study (n = 1,879) | ||||
|---|---|---|---|---|---|
| total (n = 1,191) | <36 years (n = 266) | 36–39 years (n = 320) | ≥40 years (n = 605) | ||
| Breast Surgery | |||||
| Mastectomy | 212 (17.1) | 39 (14.8) | 67 (21.4) | 106 (17.9) | 532 (29.2) |
| Mastectomy with reconstruction | 246 (21.0) | 76 (28.9) | 66 (21.1) | 104 (17.5) | n.a. |
| BCT | 711 (60.8) | 148 (56.3) | 180 (57.5) | 383 (64.6) | 1,288 (70.8) |
| Missing | 22 | 3 | 7 | 12 | 59 |
| pT1 with BCT | 395 (67.9) | 81 (64.3) | 95 (60.1) | 219 (73.2) | 849 (83.7) |
| Missing | 9 | 1 | 3 | 5 | 29 |
| Axilla Surgery | |||||
| Overall | 1,144 (100) | 263 (100) | 310 (100) | 579 (100) | 1,681 (90.8) |
| SLNB | 627 (56.8) | 127 (49.8) | 165 (53.2) | 335 (57.9) | |
| Axilla dissection | 287 (25.1) | 84 (32.9) | 83 (26.8) | 120 (20.7) | |
| SLNB + axilla dissection | 230 (20.1) | 44 (17.3) | 62 (20.0) | 124 (21.4) | |
| Missing | 47 | 3 | 10 | 26 | 28 |
| Radiation | |||||
| Overall | 1,024 (86.0) | 219 (82.3) | 279 (87.2) | 526 (86.9) | 1,595 (84.9) |
| Missing | 0 | 0 | 0 | 0 | 21 |
| Radiation after BCT | 700 (98.5) | 147 (99.3) | 177 (98.3) | 376 (98.2) | 1,248 (97.6) |
| Missing | 0 | 0 | 0 | 8 | 9 |
| Chemotherapy | |||||
| Overall | 1,061 (89.2) | 260 (97.7) | 297 (92.8) | 504 (83.3) | 1,072 (59.3) |
| Missing | 1 | 0 | 1 | 0 | 71 |
| Anti-endocrine therapy | |||||
| Overall | 865 (72.9) | 158 (59.6) | 223 (69.9) | 484 (80.4) | 1,351 (76.3) |
| SERM (tamoxifen) | 830 (96.0) | 153 (96.8) | 217 (97.3) | 460 (95.0) | |
| AI | 44 (5.1) | 6 (3.8) | 5 (2.2) | 33 (6.8) | |
| GnRH analogues | 267 (30.9) | 104 (65.8) | 108 (48.4) | 55 (11.4) | |
| Missing | 5 | 1 | 1 | 3 | 122 |
| Antibody therapy (trastuzumab) | |||||
| Overall | 264 (23.5) | 74 (29.7) | 85 (27.7) | 105 (18.5) | n.a. |
| Missing | 68 | 17 | 13 | 38 | |
BCT = Breast-conserving therapy; SLNB = sentinel lymph node biopsy; SERM = selective estrogen receptor modulator; AI = aromatase inhibitor; GnRH = gonadotropin-releasing hormone; n.a. = not available.